{"name":"Janssen R&D Ireland","slug":"janssen-r-d-ireland","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GSK2336805 120 mg","genericName":"GSK2336805 120 mg","slug":"gsk2336805-120-mg","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TVR","genericName":"TVR","slug":"tvr","indication":"Chronic hepatitis C","status":"phase_3"}]}],"pipeline":[{"name":"GSK2336805 120 mg","genericName":"GSK2336805 120 mg","slug":"gsk2336805-120-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TVR","genericName":"TVR","slug":"tvr","phase":"phase_3","mechanism":"TVR is a protease inhibitor that works by blocking the replication of the hepatitis C virus.","indications":["Chronic hepatitis C","Hepatitis C genotype 1 infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOZXFzV1pRNnlydDdCRHpBLVhrckZ5c3RzbzdxOXZFRmlXcWJmYnROX3BvcF81M1lhbkZud3NMRzF0YnZCWVlrbUNLVFBTSU9PNG5HRHNiWTIyS0FwNEdhOVBlSUdTSm9WZURGbVdoQ3I5cTZHeU9GdC1Xc3JyZzA5eWRHUTdiSzA?oc=5","date":"2025-12-15","type":"earnings","source":"RTE.ie","summary":"Profits fall by 34% to €4.47 billion at J&J's Irish unit - RTE.ie","headline":"Profits fall by 34% to €4.47 billion at J&J's Irish unit","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPR2w4bTZ0cVlUSlNNN2x6YkpGa21JT2d1X3MxXzRkeWlINE1mMDlzaTB6OHd6QWQ1YUltcVVFc21HS0NMZ2k4NlVJVW9tMUZkLThFaU4zcGYwRG8wUVg0LVBDR21xVU5YbmxaVmxDVExpdmNkaENQUkhwV2gwUi1URFJyUUpEeFpQMU9jLWh4S3FBWWlqM0xzWnVHUlBKMjF4MVE1UkUxbU1nSnNQREZNYnl2WTgzN25DWFB4NjZNWQ?oc=5","date":"2025-12-15","type":"earnings","source":"Business Post","summary":"Johnson & Johnson’s Irish subsidiary takes €2.3 billion hit to post-tax profit in 2024 - Business Post","headline":"Johnson & Johnson’s Irish subsidiary takes €2.3 billion hit to post-tax profit in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5WVnRQV015ZHVud1dXc0ZKNzg4dndkUjZrQmVKZ3J0UnJsTUFHcjY2Z0JUZWNxM29zMV9oekVZdGl3b1h1bFFCY0xnMl9Ld2tkb2RZZHZuNDY3ck1BMnNQTUdCRV9tUmVyUmFPZWRidUEyTG53WFE?oc=5","date":"2025-12-14","type":"earnings","source":"Irish Examiner","summary":"Profits at Johnson & Johnson's Cork facility decrease by 35% - Irish Examiner","headline":"Profits at Johnson & Johnson's Cork facility decrease by 35%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPak1fMzlDQ0w1Q1FaM0J6NFFoTXhQamlpMENMOXRUclkwbnNoVi1jWmNBa2ZmZjBVbmhTSlp4UFVDLUVnTXB6ZnFHQU9WVXBld3pnUzhBNHh6amxLQk9teHJKaGhkMmU2WHpfUG9ZRFJrenQ5dEhYcUg0c3UwT0tDZWVhZXJNam84N3g1azNrN0pkZXlySWN4ZXJSOWN6amNhOHNzVm5iWVZVOUtSUzRhN3BR?oc=5","date":"2025-12-14","type":"earnings","source":"The Irish Independent","summary":"Profits fall at main Irish arm of Johnson & Johnson - The Irish Independent","headline":"Profits fall at main Irish arm of Johnson & Johnson","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPZGVOOFREcURibGxXOUJ3allvMjhoWlpvQTBqdFdUR1VGS3R5bDVJOG5lRExoWWZKbWVSV0xhWHBUQ1REekZzLTVObVN4S2dFekRoN3VreVVFZ1FURnFSbFJBcFBMNVZzZ0E4MWZsaEw2SDF4b2tQTklmdE5ZajJ4eGJIS0VnUEJwWkRHbWJoY3NEYmZkZXYzeVNseFFWdHYxQUNHd2Fsdk1wYl9lNFR1T3FTNFRIMUppRDdJZXFLUGJsVUVRUkZUSHVDckNyOHlkRDd1UmRLOUVCMjdlU3FaX2xoQkJ2eTVmNXVEbXg4SVBxRDBkaVUzVTR6czY0Z3JvNHNQUm53Uk51R1Vzbjdj?oc=5","date":"2024-08-23","type":"pipeline","source":"Johnson & Johnson","summary":"Michaela Hagenhofer Appointed General Manager, Johnson & Johnson Innovative Medicine Ireland – Commercial Operations - Johnson & Johnson","headline":"Michaela Hagenhofer Appointed General Manager, Johnson & Johnson Innovative Medicine Ireland – Commercial Operations - J","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-09-23","type":"regulatory","source":"Life4me+","summary":"Achillion Pharmaceuticals and J&J Were Slightly Down in Premarket Trading After the Discontinuation of Further Hepatitis C Treatment Investigation Was Announced - Life4me+","headline":"Achillion Pharmaceuticals and J&J Were Slightly Down in Premarket Trading After the Discontinuation of Further Hepatitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNNXVWWDd3RGFXTjJqRWtlbEFGd3d2Y2c0TzdwNXVJWXpUaWxHcGtTcl8zS090UXBNQmV3VThDTm1VXzVVdzZaSmlDNk9jQVU1cHJSZGNpbEZMYkZkT3ZQWTFfY0k1UEZ0UG00S21NbENLenhYWFlKNEFfdGF2eHZuaHcyeEVVS2JiVW9nUTNsRGVWQjAtWUJGaWUwajFSMEVkQ2dkRmx6N05WM3hqMVEzUDFacFduVTlrTXozM3VORjEwdnZ6dW9qMS1EWDdJZE5BN051ZXRvYU5WX3VIb1E?oc=5","date":"2021-11-08","type":"pipeline","source":"PR Newswire UK","summary":"Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica - PR Newswire UK","headline":"Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPblpxdVl6OUo3YTg4ei1iejN2a1RjYUp4QTB4VWFxOHhyelJOWHFwZzJJQ3NhQ3hMa0RKMlBqWVNJN3p1bzBCSnB3LUQ3bDRESEtsa1Zqai0ydmFZbURuNk9WVU5jWmVlTVZXMTFYb1ZCYnQ3a05QbG1SU3NmcTZJS1RPaTYtVGZrTnBGakNVbko5UQ?oc=5","date":"2021-09-21","type":"pipeline","source":"Silicon Republic","summary":"Janssen Sciences Ireland appoints new commercial general manager - Silicon Republic","headline":"Janssen Sciences Ireland appoints new commercial general manager","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQb0ZJaUNMWGJvYjgzM0NHeU12NldCVmRzbTR5VDlEcE10X1oyN0tRbXdvTG9yQ19JRTRBOWx1WF96dTBELXhrRTBXX3lLTUw0YU1QLVB2NVNIazVmRF9KU0g0MFpqT3hsbUlPQnhISXJ1dDJnQ2toNlo5RHZ6cWthVWZzTENCLXktMm9EWEdzZlQwT1dJNS0ySUdaQWxSNEtRbzg0Y1JfbFhLOFcxYW4zUENEcGF0Nm05RTZvV0VVRkZsa3R6bEE?oc=5","date":"2021-06-22","type":"deal","source":"Fierce Pharma","summary":"J&J cell therapy partner Legend carves out production foothold in Belgium as myeloma drug nears finish line - Fierce Pharma","headline":"J&J cell therapy partner Legend carves out production foothold in Belgium as myeloma drug nears finish line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNLXpHcWtTYjhBbUFzcUVtWmw2alB2UVk0dmwtdDJPZDlUYllJdVlfQTdLVEVWdzd3UEhfMERUeG93bDNGZ1M3TEVHc240QUx6Q2lSa3gyWGxLSk9SMmtvN3VBY0pkYVpnTEU3Vi12VmhCXzBTbkhqUDY5azN3czJrVVpaREI3Wk9NT3c?oc=5","date":"2019-01-10","type":"deal","source":"pharmaphorum","summary":"EUSA Pharma buys rights to Janssen rare disease drug - pharmaphorum","headline":"EUSA Pharma buys rights to Janssen rare disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQMG5FSWpTSFFOZ3N2bUFOcDRsTno1VDFaQ0g3V0NhRTJHQ0FHM1JhRmRwaHJpOTFiaXlvRVVOMWZkU1VEWFRjZXpESFhLUnRGYXdtdVRmQ0xNNERFU1RCdjNETlJEUlhWVzA5OU1wQjdZdHFOYXQxNy0wcTFPRTV6b1dHWWx5bUdtT253aWt5TWlaenJOZXdqYURIb012Mmg3?oc=5","date":"2017-02-04","type":"pipeline","source":"Bioprocess Online","summary":"ViiV Healthcare And Janssen Collaborate On HIV Drug Combo - Bioprocess Online","headline":"ViiV Healthcare And Janssen Collaborate On HIV Drug Combo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNN3VXVnM3bXlhSVQxRGkxeHBaZ2JWdTNIUzVPNlBuc2wyLUs0Z0Y3RlRQa2x0VnBpbFRQRVYzY2xhTlhfYURkNHh3cFFaS3BBb1JySDRURUxzZS1nc1BkaDM3MkxEd3dNODFVcFBIdUN3X081a1ZLazlnR2ZtNWhfZC1uZXFDVEw1MEZ0aTJRX0p2TW9Na0tVWlVneDRNMGNOMFdmVmxRUVRmMVk4YkhsdUI1U3FpNmJtUUJfbjBqWjl3TjR6SGJxRXotMmd3OThfNlBWZUVqVUR6RU1GQkxURWs5RnhNaUJhalR5U3ByU3BtMFIzeHpiZVJzYkpfbzFWUXhEWlljSk0wLS1NTHFfMXlwWi1kc1lNX1Zj?oc=5","date":"2014-12-29","type":"deal","source":"PR Newswire","summary":"Janssen Announces Collaboration with Gilead to Develop PREZISTA®-based Single-tablet Regimen for the Treatment of People Living with HIV - PR Newswire","headline":"Janssen Announces Collaboration with Gilead to Develop PREZISTA®-based Single-tablet Regimen for the Treatment of People","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}